Results 101 to 110 of about 15,210 (229)

High‐Sensitive Mass Cytometry Metal Tags Based on Noble Metal Nanoparticles Assisting Acute Myeloid Leukemia Immune Checkpoint Profiling

Advanced Science, Volume 13, Issue 25, 4 May 2026.
ABSTRACT Mass cytometry is optimal for acute leukemia immune checkpoint profiling. However, current commercial metal‐chelating polymer (MCP) metal tags limit its sensitivity due to low metal loading capacity. We report a novel synthetic strategy employing antibody‐conjugated gold or platinum nanoparticles (AuNP/PtNP) for high‐dimensional single‐cell ...
Zhizhou Liu, Yu Yang, Lingfei Qiu, Yi Yang, Jingrui Li, Juan Yue, Yinghui Li, Yingdai Gao, Pengli Bai   +8 more
wiley   +1 more source

Clinical Characteristics, Gene Mutation Profiles and Prognosis of Patients With Acute Myeloid Leukemia Carrying PHF6 Mutations

Cancer Medicine, Volume 15, Issue 5, May 2026.
ABSTRACT Background Plant Homeodomain Finger Protein 6 (PHF6) gene mutations are rare in acute myeloid leukemia (AML), with unclear mechanisms and uncertain prognostic value. They may compromise risk stratification and treatment decisions. This study analyzed clinical features and survival outcomes in PHF6‐mutated AML patients, evaluating the impact of
Dongmei Wang, Hanzhang Pan, Yungui Wang, Huan Xu, Lin Liu, Yuting Xu, Hongyan Tong   +6 more
wiley   +1 more source

Targeting the nuclear export receptor exportin‐1 in acute myeloid leukaemia: From biology to clinical translation

Clinical and Translational Medicine, Volume 16, Issue 5, May 2026.
• XPO1 hyperactivation promotes leukaemogenesis by altering nucleocytoplasmic transport and transcriptional control in acute myeloid leukaemia (AML). • Selinexor and eltanexor show preferential activity in NPM1‐mutated, DEK::NUP214‐positive and SF3B1‐mutated myeloid neoplasms.
Yifan Liu, Xiaoya Yun, Weidong Ding, Suxiao Li, Hui Liu   +4 more
wiley   +1 more source

A case of atypical prolonged hematologic toxicity with azacitidine in Chronic Myelomonocytic Leukemia (CMML), review of literature and a proposal of management

Mediterranean Journal of Hematology and Infectious Diseases, 2012
Hypomethylating drugs are useful and approved in the management of myelodysplastic syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML). However, phase 2 and 3 studies that assessed these agents in MDS, have included only a small number of CMML ...
Elena Elli, Caterina Cecchetti, Angelo Belotti, Lorenza Borin, Enrico Maria Pogliani   +4 more
doaj   +1 more source

Isocitrate Dehydrogenase Mutations in Cancer: From Bench to Bedside Applications

MedComm, Volume 7, Issue 5, May 2026.
Mutant isocitrate dehydrogenase affects multiple cancer types. Alterations in IDH1 and IDH2 result in abnormal enzyme activity, leading to the overproduction of D‐2‐hydroxyglutarate (D‐2HG). This metabolite disrupts cellular metabolism and epigenetic regulation, driving cancer initiation, progression, and metastasis.
Yuhan Fang, Xiaoqing Wang, Kai Luo, Tikam Chand Dakal, He Bai, Caiming Xu, Guixin Zhang   +6 more
wiley   +1 more source

Epigenetic analyses suggest different pathways during pregnancy for development of type 1 diabetes in children with high versus low‐neutral human leukocyte antigen‐risk

Journal of Internal Medicine, Volume 299, Issue 5, Page 570-586, May 2026.
Abstract Background and objective The development of Type 1 diabetes (T1D) is shaped by genetic predisposition and epigenetic regulation. Human leukocyte antigen (HLA) risk alleles are major genetic determinants, but the epigenetic landscape in relation to disease onset remains unclear.
Shamila D. Alipoor, Angelica Ahrens, Julia Åkesson, Thomas Hillerton, Mika Gustafsson, Maria Lerm, Johnny Ludvigsson   +6 more
wiley   +1 more source

A phase 1 study of ASTX727 plus talazoparib in patients with triple‐negative or hormone resistant/HER2‐negative metastatic breast cancer

Cancer, Volume 132, Issue 8, 15 April 2026.
Abstract Background Poly(adenosine diphosphate ribose) polymerase (PARP) is recruited to DNA damage sites along with epigenetic factors such as DNA methyltransferase 1 (DNMT1). Inhibitors of DNMT modulate reactive oxygen species (ROS)‐cyclic adenosine monophosphate (cAMP)/Protein Kinase A signaling and induce a “BRCAness phenotype” that further ...
Kathy D. Miller, Alexandra Thomas, Sandra Althouse, Yong Zang, Erin Conder, Ryan Burgos, Bryan P. Schneider, Tarah Ballinger, Emily Douglas, Katherine Ansley, H. Josh Jang, Woonbok Chung, Jean‐Pierre Issa, Kenneth P. Nephew, Feyruz V. Rassool   +14 more
wiley   +1 more source

Current status and research directions in acute myeloid leukemia

Blood Cancer Journal
The understanding of the molecular pathobiology of acute myeloid leukemia (AML) has spurred the identification of therapeutic targets and the development of corresponding novel targeted therapies.
Hagop Kantarjian, Gautam Borthakur, Naval Daver, Courtney D. DiNardo, Ghayas Issa, Elias Jabbour, Tapan Kadia, Koji Sasaki, Nicholas J. Short, Musa Yilmaz, Farhad Ravandi   +10 more
doaj   +1 more source

Daily practice management of myelodysplastic syndromes in France: data from 907 patients in a one-week cross-sectional study by the Groupe Francophone des Myélodysplasies

Haematologica, 2010
Background There is little published information on the everyday clinical management of myelodysplastic syndromes in real world practice.Design and Methods We conducted a cross-sectional study of all patients with myelodysplastic syndromes attending 74 ...
Charikleia Kelaidi, Aspasia Stamatoullas, Odile Beyne-Rauzy, Emmanuel Raffoux, Bruno Quesnel, Agnes Guerci, François Dreyfus, Sabine Brechignac, Christian Berthou, Thomas Prebet, Yosr Hicheri, Maya Hacini, Jacques Delaunay, Marie-Pierre Gourin, Jean-Marie Camo, Hacene Zerazhi, Anne-Laure Taksin, Laurence Legros, Bachra Choufi, Pierre Fenaux   +19 more
doaj   +1 more source

Venetoclax-based therapy for relapsed or refractory acute myeloid leukemia: latest updates from the 2023 ASH annual meeting

Experimental Hematology & Oncology
Patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) often exhibit limited responses to traditional chemotherapy, resulting in poor prognosis.
Xubo Gong, Xin He, Lin Wang, Teng Yu, Weiwei Liu, Huiying Xu, Lan Jin, Xiang Li, Bin Zhang, Zhihua Tao, Wenbin Qian   +10 more
doaj   +1 more source